# OnCo record paper-murano-venetoclax-rituximab-nejm-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-murano-venetoclax-rituximab-nejm-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-murano-venetoclax-rituximab-nejm-2018" ;
  schema:name "MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL"@en ;
  schema:description "In relapsed CLL, a time-limited venetoclax-rituximab course cut progression risk by more than 80% compared with bendamustine-rituximab and later improved survival."@en ;
  schema:url <https://onco.cc/key-papers/paper-murano-venetoclax-rituximab-nejm-2018/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1713976>, <https://clinicaltrials.gov/study/NCT02005471> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1713976> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Seymour JF, Kipps TJ, Eichhorst B, et al." ;
  onco:related <https://onco.cc/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/> ;
  onco:cancers <https://onco.cc/cancers/cll/> ;
  onco:targets <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/cd20/> ;
  onco:drugs <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/bendamustine/> ;
  onco:companies <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/del17p-tp53/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-resistance/> ;
  onco:journals <https://onco.cc/journals/nejm/> .